The abstract is read at the publisher; the summary is JClub's.
Syncytial CAR macrophages fused with neutrophils (S-CAR-Ms) accumulate in tumors more than conventional CAR-Ms and enable efficient phagocytosis via scFv-antigen and PtdSer-MerTK pathways.
- Why it matters: Conventional CAR-M therapy is limited in solid tumors by poor infiltration, weakened effector function, and immune escape from target antigen-low cells.
- What they did: The team fused CAR-Ms with neutrophils to create S-CAR-Ms, using chemokine-driven migration plus neutrophil-derived extracellular traps and reactive oxygen species to raise PtdSer exposure.
- The result: In syngeneic and xenograft mouse models, a single dose reduces tumor burden, limits metastasis, prevents recurrence, and triggers antigen spreading to minimize escape by antigen-low tumors.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.